HER2+  	HER2+  	 NNP	B-NP
breast  	breast  	 NN	O
cancer 	cancer 	 NN	O
:  	:  	 :	O
how  	how  	 WRB	O
to  	to  	 TO	O
evaluate 	evaluate 	 VB	O
?  	?  	 .	O
Approximately  	Approximately  	 RB	O
15 	15 	 CD	O
% 	% 	 NN	O
-30 	-30 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
breast  	breast  	 JJ	O
cancers  	cancers  	 NNS	O
have  	have  	 VBP	O
overexpression  	overexpression  	 VBN	O
or  	or  	 CC	O
amplification  	amplification  	 NN	B-NP
of  	of  	 IN	O
human  	human  	 JJ	B-NP
epidermal  	epidermal  	 JJ	I-NP
growth  	growth  	 NN	I-NP
factor  	factor  	 NN	I-NP
receptor  	receptor  	 NN	I-NP
2  	2  	 CD	I-NP
( 	( 	 -LRB-	O
HER2 	HER2 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
which  	which  	 WDT	O
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
worse  	worse  	 JJR	B-NP
prognosis  	prognosis  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
absence  	absence  	 NN	B-NP
of  	of  	 IN	O
therapy 	therapy 	 NN	O
.  	.  	 .	O
While  	While  	 IN	O
HER2  	HER2  	 CD	B-NP
testing  	testing  	 NN	I-NP
is  	is  	 VBZ	O
common  	common  	 JJ	O
there  	there  	 EX	O
are  	are  	 VBP	O
issues  	issues  	 NNS	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
its  	its  	 PRP$	O
sensitivity  	sensitivity  	 NN	O
and  	and  	 CC	O
specificity 	specificity 	 NN	O
,  	,  	 ,	O
which  	which  	 WDT	O
may  	may  	 MD	O
impact  	impact  	 VB	O
the  	the  	 DT	O
perceived  	perceived  	 JJ	O
usefulness  	usefulness  	 NN	O
of  	of  	 IN	O
treatments 	treatments 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
objectives  	objectives  	 NNS	O
of  	of  	 IN	O
this  	this  	 DT	O
review  	review  	 NN	O
are  	are  	 VBP	O
to  	to  	 TO	O
understand  	understand  	 VB	O
the  	the  	 DT	O
characteristics  	characteristics  	 NNS	O
and  	and  	 CC	O
peculiarities  	peculiarities  	 NNS	O
of  	of  	 IN	O
HER2+  	HER2+  	 CD	B-NP
breast  	breast  	 NN	O
cancer 	cancer 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
to  	to  	 TO	O
discuss  	discuss  	 VB	O
the  	the  	 DT	O
issues  	issues  	 NNS	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
correlation  	correlation  	 NN	O
of  	of  	 IN	O
HER2  	HER2  	 CD	B-NP
immunogenicity  	immunogenicity  	 NN	I-NP
with  	with  	 IN	O
therapeutic  	therapeutic  	 JJ	B-NP
response 	response 	 NN	I-NP
,  	,  	 ,	O
especially  	especially  	 RB	O
of  	of  	 IN	O
trastuzumab 	trastuzumab 	 NN	B-NP
.  	.  	 .	O
There  	There  	 EX	O
are  	are  	 VBP	O
two  	two  	 CD	O
issues  	issues  	 NNS	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
correlation  	correlation  	 NN	O
between  	between  	 IN	O
HER2  	HER2  	 CD	B-NP
immunogenicity  	immunogenicity  	 NNS	I-NP
and  	and  	 CC	O
therapeutic  	therapeutic  	 JJ	B-NP
response 	response 	 NN	I-NP
:  	:  	 :	O
possible  	possible  	 JJ	O
resistance  	resistance  	 NN	O
to  	to  	 TO	O
trastuzumab  	trastuzumab  	 VB	O
through  	through  	 IN	O
lack  	lack  	 NN	O
of  	of  	 IN	O
phosphatase  	phosphatase  	 NN	B-NP
and  	and  	 CC	O
tensin  	tensin  	 JJ	B-NP
analog  	analog  	 NN	I-NP
or  	or  	 CC	O
receptor  	receptor  	 JJ	B-NP
expression 	expression 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
nonspecific  	nonspecific  	 NNS	B-NP
or  	or  	 CC	O
insensitive  	insensitive  	 JJ	B-NP
measurement  	measurement  	 NN	I-NP
of  	of  	 IN	I-NP
HER2  	HER2  	 CD	I-NP
expression 	expression 	 NN	I-NP
.  	.  	 .	O
These  	These  	 DT	O
issues  	issues  	 NNS	O
can  	can  	 MD	O
be  	be  	 VB	O
addressed  	addressed  	 VBN	O
through  	through  	 IN	O
the  	the  	 DT	O
evaluation  	evaluation  	 NN	O
of  	of  	 IN	O
other  	other  	 JJ	O
factors  	factors  	 NNS	O
in  	in  	 IN	O
addition  	addition  	 NN	O
to  	to  	 TO	O
HER2  	HER2  	 CD	B-NP
status  	status  	 NN	I-NP
at  	at  	 IN	O
diagnosis 	diagnosis 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
improvements  	improvements  	 NNS	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
performance  	performance  	 NN	O
and  	and  	 CC	O
validation  	validation  	 NN	B-NP
of  	of  	 IN	I-NP
HER2  	HER2  	 CD	I-NP
testing 	testing 	 NN	I-NP
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
important  	important  	 JJ	O
that  	that  	 IN	O
HER2  	HER2  	 CD	B-NP
tests  	tests  	 NNS	I-NP
are  	are  	 VBP	O
of  	of  	 IN	O
the  	the  	 DT	O
highest  	highest  	 JJS	O
quality  	quality  	 NN	O
and  	and  	 CC	O
that  	that  	 IN	O
laboratories  	laboratories  	 NNS	O
performing  	performing  	 VBG	O
the  	the  	 DT	O
tests  	tests  	 NNS	O
are  	are  	 VBP	O
assessed  	assessed  	 VBN	O
and  	and  	 CC	O
validated  	validated  	 JJ	O
correctly 	correctly 	 NN	O
.  	.  	 .	O
Pathologists  	Pathologists  	 NNP	O
must  	must  	 MD	O
proactively  	proactively  	 RB	O
monitor  	monitor  	 VB	O
the  	the  	 DT	O
quality  	quality  	 NN	O
of  	of  	 IN	O
their  	their  	 PRP$	O
tests  	tests  	 NNS	O
and  	and  	 CC	O
oncologists  	oncologists  	 NNS	B-NP
should  	should  	 MD	O
ensure  	ensure  	 VB	O
that  	that  	 IN	O
all  	all  	 DT	O
breast  	breast  	 NN	O
cancer  	cancer  	 NN	O
cases  	cases  	 NNS	O
are  	are  	 VBP	O
assessed  	assessed  	 VBN	O
for  	for  	 IN	O
HER2 	HER2 	 NNP	B-NP
,  	,  	 ,	O
as  	as  	 RB	O
only  	only  	 RB	O
then  	then  	 RB	O
can  	can  	 MD	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
benefit  	benefit  	 VBP	O
from  	from  	 IN	O
specific  	specific  	 JJ	O
and  	and  	 CC	O
appropriate  	appropriate  	 JJ	O
therapy 	therapy 	 NN	O
.  	.  	 .	O
